A researcher from Swiss biopharmaceutical company AC Immune will present findings on the company's alpha-synuclein-PET tracer program at the virtual 2020 Alzheimer's Association International Conference (AAIC).
During a 28 June presentation, AC Immune research scientist Francesca Capotosti, PhD, will discuss the development of a PET tracer for the diagnosis of a‑synucleinopathies, which can help in the diagnosis of Parkinson's disease. The presentation will take place during a panel covering non-Alzheimer's neurodegenerative disorders at the conference.
The company will also have research on a phase IB clinical trial of its anti-Abeta vaccine ACI-24 presented at AAIC. The trial is the first large, multinational study on clinical and biomarker changes of Down-syndrome-related Alzheimer's disease, according to AC Immune.
